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Schnitzler syndrome is an underdiagnosed clinical
condition characterized by 2 major criteria: chronic
recurrent urticarial eruption and monoclonal IgM
gammopathy, as well as at least 2 of the following
minor criteria: (1) recurrent fever, (2) high C-reactive
protein (CRP) levels, (3) signs of abnormal bone
remodeling with or without bone pain, and (4)
neutrophilic infiltrates on skin biopsy.1 We report
the case of a patient with history of hairy cell
leukemia who exhibited atypical clinical presenta-
tion of chronic urticaria for 2 years before the final
diagnosis of Schnitzler syndromewas established. To
the best of our knowledge, this is the first reported
case of Schnitzler syndrome associated with hairy
cell leukemia.CASE REPORT
In 2013, a 50-year-old man presented with com-
plaints of arthralgia involving knees, ankles, and
fingers, which primarily manifested during the night.
A fewmonths later, he developed recurrent episodes
of a nonpruritic urticarial eruption. His relevant
medical history consisted of hairy cell leukemia in
2010, in remission after treatment with cladribine yet
with small residual disease.
Physical examination confirmed diffuse labile
erythematous macules and wheals (Fig 1). The
lesions usually disappeared within 24 to 48 hours
without associated angioedema. Laboratory tests
found a normal blood count, increased CRP levelsDepartments of Dermatology,a Internal Medicine,c and
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. E-mail: valerie.dekeuleneer@uclouvain.be.at 18.2 mg/L (normal,\6.0 mg/L), and an erythro-
cyte sedimentation rate at 32 mm/h (normal,
\14 mm/h). Results were negative for antinuclear
antibodies. Serum IgG, IgA, and IgM levels were
within normal ranges.
Bone scintigraphy found a diffuse area of
increased uptake in the distal third of both the
femoral diaphysis and epiphysis. Bone marrow
biopsy found a persistent population of malignant
B lymphocytes but no aggressive lymphoma. Skin
biopsy detected mild edema of the dermis with
perivascular and interstitial infiltrates of lympho-
cytes, histiocytes, and numerous eosinophils.
In 2014, a diagnosis of spontaneous chronic
urticaria was proposed, and the patient was initially
treated with high doses of different antihistamines,
such as rupatadine, cetirizine, and others, during
3 months without significant response. Oral cortico-
therapy was then administered for 1 month without
any success. Next, treatment with subcutaneous
omalizumab (2 3 150 mg/mo) for 6 months was
proven inefficient. In March 2015, a new serum
protein electrophoresis detected for the first time a
thin band of IgM-k monoclonal gammopathy. On
additional laboratory tests, there was an increasedJAAD Case Reports 2018;4:386-9.
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Fig 1. Schnitzler syndrome. Diffuse labile erythematous
macules and wheals.
Fig 2. Skin biopsy. Perivascular and interstitial dermal
infiltrate consisting of lymphocytes, histiocytes, eosino-
phils, and a lot of neutrophils.
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Fank et al 387CRP level at 21.0 mg/L, and serum IgMwasmeasured
at 1.92 g/L (normal range, 0.4-2.3 g/L).
A second skin biopsy found a perivascular and
interstitial dermal infiltrate consisting of lympho-
cytes, histiocytes, eosinophils, and many neutro-
phils. A discrete number of leukocytoclastic foci
were observed in the dermis, without sign of
vasculitis (Fig 2).
Based on the clinical presentation and additional
investigation results, a diagnosis of Schnitzler syn-
drome was proposed in April 2015. The patient
exhibited the 2 obligatory criteria according to the
Strasbourg diagnostic criteria for Schnitzler syn-
drome, namely, a chronic recurrent urticarial erup-
tion and monoclonal IgM gammopathy, in addition
to 4 minor criteria (high CRP levels, signs of
abnormal bone remodeling with bone pain, and
neutrophil infiltrate on the skin biopsy).1,2
The patient was first treated with colchicine and
nonsteroidal anti-inflammatory drugs, which slightly
improved his symptoms. Dapsone was later added,
although not tolerated by the patient. On account of
prior leukemia, administering immunosuppressive
agents like cyclosporin was contraindicated. In July
2015, anakinra (Kineret; Sobi, Stockholm, Sweden),
an antieinterleukin-1 (IL-1) monoclonal antibody,
was injected subcutaneously at a daily dose of
100mg (Fig 3). The symptoms significantly improved
within 48 hours, with the skin rash and hand and
ankle arthralgia completely disappearing, yet
continued mild knee arthralgia. The inflammatory
parameters were negative (CRP \1.0 mg/L), and
total serum IgM decreased slightly (1.62 g/L),
whereas a thin band of monoclonal IgM-k persisted.
The neutrophil count decreased after anakinra
initiation (1740 cells/mm3). In July 2016, 1 year afterthe first anakinra injection, the patient reported
marked improvement in his quality of life, yet the
skin rash systematically reappeared within 24 to
48 hours whenever therapy was discontinued.DISCUSSION
Schnitzler syndrome is an underdiagnosed, ac-
quired autoinflammatory syndrome that must be
considered in the differential diagnosis of chronic
urticaria. It is essential to continually perform com-
plementary investigations, particularly when the
urticaria appears atypical, such as associated with
extracutaneous manifestations, and in the lack of
response to the usual treatment. To date, more than
281 cases have been reported since its first descrip-
tion in 1972 by French dermatologist Liliane
Schnitzler.1 Most cases are not diagnosed before
5 years.3 In our patient, the diagnosis was established
after 2 years. The proven efficacy of new biological
therapies, such as IL-1 receptor antagonist (anakinra,
Kineret), has now clearly established them as treat-
ment of choice in the Schnitzler syndrome.1,4-8
The originality of this case is the association
between Schnitzler syndrome and hairy cell leuke-
mia, which was never reported before. Recent
studies have found that pro-inflammatory cytokine
IL-1 has a crucial role in the pathogenesis of
Schnitzler syndrome.9,10 It was also recently found
that a systemic overproduction of IL-1ß in the
Schnitzler syndrome, caused by mutations in the
inflammasome, results in a profound loss of anti-
inflammatory helper T-cell 17 cell functionalities.
This phenomenon can be reversed by antieIL-1ß
treatment. The role of the IgM paraprotein in the
pathogenesis of the Schnitzler syndrome remains
unclear. In our patient, the link between his history
of leukemia and this current condition was prob-
ably due to a persistent residual disease that consists
of a monoclonal population of B lymphocytes
secreting a monoclonal IgM. This monoclonal IgM
can be responsible for the autoactivation of
Fig 3. Timeline of exacerbations and response to the various drugs from start of the different
symptoms to the final diagnosis of Schnitzler syndrome.
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native explanation could be the secretion of other
inflammatory cytokines by the leukemic cells that
results in IL-1ß secretion. Other patients withSchnitzler syndrome may have secondary hemato-
logic malignancies in 15% to 20% of the cases as
seen in other monoclonal IgM gammopathies of
undetermined significance.7,11
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